Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: health-related quality-of-life results from KEYNOTE-048 (2022)
- Authors:
- Autor USP: CASTRO JUNIOR, GILBERTO DE - FM
- Unidade: FM
- DOI: 10.1016/j.oraloncology.2022.105815
- Subjects: RECIDIVA LOCAL DE NEOPLASIA; NEOPLASIAS DE CABEÇA E PESCOÇO; RECIDIVA LOCAL DE NEOPLASIA; ENSAIO CLÍNICO; QUIMIOTERAPIA; IMUNOTERAPIA; CARCINOMA DE CÉLULAS ESCAMOSAS
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Oral oncology
- ISSN: 1368-8375
- Volume/Número/Paginação/Ano: v. 128, article ID 105815, 12p, 2022
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: hybrid
- Licença: cc-by-nc-nd
-
ABNT
RISCHIN, Danny et al. Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: health-related quality-of-life results from KEYNOTE-048. Oral oncology, v. 128, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.oraloncology.2022.105815. Acesso em: 06 nov. 2024. -
APA
Rischin, D., Harrington, K. J., Greil, R., Soulieres, D., Tahara, M., Castro Junior, G. de C., et al. (2022). Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: health-related quality-of-life results from KEYNOTE-048. Oral oncology, 128. doi:10.1016/j.oraloncology.2022.105815 -
NLM
Rischin D, Harrington KJ, Greil R, Soulieres D, Tahara M, Castro Junior G de C, Psyrri A, Brana I, Neupane P, Bratland A. Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: health-related quality-of-life results from KEYNOTE-048 [Internet]. Oral oncology. 2022 ; 128[citado 2024 nov. 06 ] Available from: https://doi.org/10.1016/j.oraloncology.2022.105815 -
Vancouver
Rischin D, Harrington KJ, Greil R, Soulieres D, Tahara M, Castro Junior G de C, Psyrri A, Brana I, Neupane P, Bratland A. Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: health-related quality-of-life results from KEYNOTE-048 [Internet]. Oral oncology. 2022 ; 128[citado 2024 nov. 06 ] Available from: https://doi.org/10.1016/j.oraloncology.2022.105815 - Diagnóstico de mutações ativadoras do gene EGFR em adenocarcinomas pulmonares: caracterização e implicações clínicas
- Efficacy and safety of ceritinib (450 mg/d or 600 mg/d) with food versus 750-mg/d fasted in patients with ALK receptor tyrosine kinase (ALK)-Positive NSCLC: primary efficacy results from the ASCEND-8 study
- Extraoral photobiomodulation for prevention of oral and oropharyngeal mucositis in head and neck cancer patients: interim analysis of a randomized, double-blind, clinical trial
- Manual de oncologia torácica
- Lung Cancer in Brazil [Editorial]
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- Noções de oncologia torácica
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
- Pembrolizumab alone or with chemotherapy for recurrent/metastatic had and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed death Ligand-1 combined positive score
- Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03)
Informações sobre o DOI: 10.1016/j.oraloncology.2022.105815 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
